Duvelisib is a selective PI3K-δ and PI3K-γ inhibitor used in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It inhibits PI3K-mediated signaling, inducing apoptosis in malignant B-cells. Duvelisib API is manufactured under GMP-compliant conditions and is suitable for oral solid dosage formulations, including capsules.

Duvelisib API is manufactured and supplied by Artis Biotech | ASTANDARDS, ensuring high purity, consistent quality, and regulatory-compliant specifications. Our APIs are produced using validated processes and are suitable for research, development, and pharmaceutical manufacturing applications.